Authors’ reply to ElshimyBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h5115 (Published 30 September 2015) Cite this as: BMJ 2015;351:h5115
- Anthony D Ormerod, emeritus professor of dermatology1,
- Kim S Thomas, professor of applied dermatology research2
- 1Division of Applied Medicine, Aberdeen University, Aberdeen, UK
- 2Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK
Elshimy’s thoughtful and important comments provide us with the opportunity to clarify points not covered in the full paper owing to space constraints.1 2 Patients taking rosuvastatin were not included because the summary of product characteristics for this statin stated at the time the study began that its use in combination with ciclosporin was contraindicated, owing to the risk of myopathy and rhabdomyolysis. This restriction has since been extended to other statins.
In response to the second point, when designing the study of this pragmatic trial, we considered performing a double blind trial but thought that this would not …